Can Janssen Revive Its Key Remicade Patent? Federal Circuit Hears Pitch
Executive Summary
Oral arguments suggest Janssen may have difficulty getting reversal of district court and patent office rulings that its composition patent is invalid.
You may also be interested in...
Remicade Patent Fight: Janssen Loses Big, But Pfizer Not Out Of Woods
Pfizer would still be at risk for damages from biosimilar launch if Janssen's manufacturing process patent is upheld even as US Federal Circuit affirms that patent covering Remicade's active ingredient is invalid.
Remicade Patent Fight: Janssen Loses Big, But Pfizer Not Out Of Woods
Pfizer would still be at risk for damages from biosimilar launch if Janssen's manufacturing process patent is upheld even as US Federal Circuit affirms that patent covering Remicade's active ingredient is invalid.
Biosimilar Legal Landscape: Lessons From 2017
In several firsts last year, US Supreme Court ruled on BPCIA, Amgen won a damages award in infringement litigation, and Amgen and Mylan inked deals clearing way for future launch of Humira and Herceptin biosimilars. Chart includes status of 15 cases and questions teed up for courts to tackle in 2018.